Bigfoot Biomedical

Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes. The company developing an end-to-end type 1 diabetes management system using a simple design, cloud connectivity, and human-centered automation. It optimizes the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care.

Biofoot Biomedical ’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. By employing data-driven intelligence across an integrated device ecosystem, they are transforming diabetes care with a fully comprehensive digital drug delivery platform experienced as a service.

Bigfoot Biomedical headquartered in United States, North America, operates in the Big Data, Artificial Intelligence (AI), Predictive Analytics, Health Care, mHealth, Medical Device, Diabetes sector. The company focuses on Big Data and has secured $45.8B in funding across 224 round(s). With a team of 101-250 employees, Bigfoot Biomedical is actively contributing to advancements in Big Data. Their latest funding round, Seed Round - Bigfoot Biomedical, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.